enGene Therapeutics Inc. (ENGN)

SEC filing

enGene Therapeutics Inc.

ENGN · CIK 1980845

4 · Sep 24, 2026 · Director, Interim Chief Medical Officer Grossman William bought 5,102 Common Shares at $1.97/unit ($10,051)

Director, Interim Chief Medical Officer Grossman William bought 5,102 Common Shares at $1.97/unit ($10,051)

xslF345X06/ownership.xml

xslF345X06/ownership.xmlSEC.gov

Graphics and non-inline formats (not embedded below).